SDZ SER 082
Latest Information Update: 06 Jan 1999
At a glance
- Originator Novartis
- Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 06 Jan 1999 No-Development-Reported for CNS disorders in Switzerland (Unknown route)
- 18 Mar 1996 New profile
- 18 Mar 1996 Preclinical development for CNS disorders in Switzerland (Unknown route)